Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: AST
  • CUSIP:
Key Metrics:
  • Previous Close: $3.90
  • 50 Day Moving Average: $4.17
  • 200 Day Moving Average: $4.00
  • 52-Week Range: $2.30 - $5.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.74
  • P/E Growth: 0.00
  • Market Cap: $178.72M
  • Outstanding Shares: 46,422,000
  • Beta: 1.58
Additional Links:
Companies Related to Asterias Biotherapeutics:

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
9/14/2016FBR & CoReiterated RatingBuyView Rating Details
9/11/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details
5/5/2015Lake Street CapitalInitiated CoverageBuy$22.00View Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.00View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.60View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
DateHeadline
News IconMarket Scout: Looking at the Levels for Asterias Biotherapeutics Inc (AST) - Providence Standard (NYSEMKT:AST)
providencestandard.com - February 27 at 8:29 AM
News IconStock Levels in Review for Asterias Biotherapeutics Inc (AST) - Davidson Register (NYSEMKT:AST)
davidsonregister.com - February 25 at 3:34 PM
News IconPT & Stock Review on Asterias Biotherapeutics, Inc. (ASX:AST) Crown Crafts, Inc. (NASDAQ:CRWS) - Davidson Register (NYSEMKT:AST)
davidsonregister.com - February 23 at 1:44 AM
News IconMarket Review: Focusing on This Stock: Asterias Biotherapeutics Inc (AST) - Rives Journal (NYSEMKT:AST)
rivesjournal.com - February 23 at 1:44 AM
News IconChecking the Metrics on Shares of Asterias Biotherapeutics, Inc. (AMEX:AST) - Midway Monitor (NYSEMKT:AST)
midwaymonitor.com - February 23 at 1:44 AM
4-traders.com logoBioTime : Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary (NYSEMKT:AST)
www.4-traders.com - February 22 at 11:21 AM
investopedia.com logoBioTime Reports $56M Non-Cash Gain On Deconsolidation (NYSEMKT:AST)
www.investopedia.com - February 22 at 11:21 AM
streetinsider.com logoBioTime (BTX) Reports Deconsolidation of OncoCyte Inc.'s Financial Statements (NYSEMKT:AST)
www.streetinsider.com - February 21 at 3:57 PM
tmcnet.com logoBioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary (NYSEMKT:AST)
www.tmcnet.com - February 21 at 9:11 AM
News IconStock Levels in Review for Asterias Biotherapeutics Inc. (AST) - Benton Bulletin (NYSEMKT:AST)
bentonbulletin.com - February 18 at 9:45 AM
News IconShares to Watch: Indicator Update on Asterias Biotherapeutics Inc. (AST) - Baldwin Journal (NYSEMKT:AST)
baldwinjournal.com - February 13 at 4:11 PM
News IconAsterias Biotherapeutics, Inc. (AST) Q4 Earnings: Investors should be expecting a very good quarter - Post Analyst (NYSEMKT:AST)
postanalyst.com - February 13 at 4:11 PM
News IconAsterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position - OrthoSpineNews (NYSEMKT:AST)
www.orthospinenews.com - February 6 at 3:43 PM
us.rd.yahoo.com logoAsterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position (NYSEMKT:AST)
us.rd.yahoo.com - February 5 at 1:48 AM
reuters.com logoBRIEF-Asterias Biotherapeutics extends expiration date of certain warrants - Reuters (NYSEMKT:AST)
www.reuters.com - February 3 at 8:52 PM
finance.yahoo.com logoAsterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position - Yahoo Finance (NYSEMKT:AST)
finance.yahoo.com - February 3 at 3:50 PM
News IconIncrease in Volatility Draws Attention to Shares of Asterias Biotherapeutics, Inc. (:AST) - Wall Street Beacon (NYSEMKT:AST)
wsbeacon.com - February 1 at 3:47 PM
News IconTrading Corner: Focusing in on Shares of Asterias Biotherapeutics, Inc. (AMEX:AST) - Gilbert Daily (NYSEMKT:AST)
gilbertdaily.com - January 29 at 8:38 PM
News IconInvestor Technical Review for Asterias Biotherapeutics Inc. (AST) - Rives Journal (NYSEMKT:AST)
rivesjournal.com - January 28 at 3:40 PM
News IconFree Cash Flow Score in Focus for Asterias Biotherapeutics, Inc. (AMEX:AST) - The Tribune (NYSEMKT:AST)
lakecitytribune.com - January 27 at 4:49 PM
marketexclusive.com logoAsterias Biotherapeutics, Inc. (NYSEMKT:AST) Files An 8-K Regulation FD Disclosure (NYSEMKT:AST)
marketexclusive.com - January 26 at 4:04 PM
News IconEnlivened Volatility Spotted in Shares of Asterias Biotherapeutics, Inc. (:AST) - Wall Street Beacon (NYSEMKT:AST)
wsbeacon.com - January 25 at 3:46 PM
4-traders.com logoASTERIAS BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) (NYSEMKT:AST)
www.4-traders.com - January 25 at 2:10 AM
News IconReviewing Indicator Levels for Asterias Biotherapeutics Inc. (AST) - Sherwood Daily (NYSEMKT:AST)
sherwooddaily.com - January 24 at 9:08 PM
News IconTurbulence Hits These Shares as Volume Spikes: Asterias Biotherapeutics, Inc. (:AST) - Wall Street Beacon (NYSEMKT:AST)
wsbeacon.com - January 24 at 9:08 PM
News IconGenerating improvement in spinal cord injuries (NYSEMKT:AST)
scienceblog.com - January 24 at 4:06 PM
streetinsider.com logoAsterias Bio (AST) Announces Efficacy Results at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical SCI (NYSEMKT:AST)
www.streetinsider.com - January 24 at 4:06 PM
finance.yahoo.com logoAsterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment … (NYSEMKT:AST)
finance.yahoo.com - January 24 at 4:06 PM
reuters.com logoBRIEF-Asterias Biotherapeutics reports positive efficacy results from company's ongoing scistar phase 1/2a clinical trial (NYSEMKT:AST)
www.reuters.com - January 24 at 4:06 PM
us.rd.yahoo.com logoAsterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries (NYSEMKT:AST)
us.rd.yahoo.com - January 24 at 4:06 PM
us.rd.yahoo.com logo7:12 am Asterias Biotherapeutics announces 'positive' efficacy results from its SCiStar Phase 1/2a clinical trial that showed additional motor function improvement at 6 to 9 months; expects to report 12-month data during 3Q17 (NYSEMKT:AST)
us.rd.yahoo.com - January 24 at 4:06 PM
seekingalpha.com logoConnecting The Dots On Asterias Biotherapeutics... (NYSEMKT:AST)
seekingalpha.com - January 23 at 8:44 PM
News IconUpdate on Valuation Formula's For Asterias Biotherapeutics, Inc. (AMEX:AST) - The Tribune (NYSEMKT:AST)
lakecitytribune.com - January 23 at 3:44 PM
News IconTechnicals in Focus for Asterias Biotherapeutics Inc. (AST) - Sherwood Daily (NYSEMKT:AST)
sherwooddaily.com - January 22 at 3:38 PM
News IconMA Levels in Review for Asterias Biotherapeutics Inc. (AST) - Rives Journal (NYSEMKT:AST)
rivesjournal.com - January 21 at 2:44 AM
News IconSmall-Cap Biotech Watchlist: Takeaways for Investors (NYSEMKT:AST)
www.investorideas.com - January 20 at 4:41 PM
4-traders.com logoAsterias Biotherapeutics : Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study (NYSEMKT:AST)
www.4-traders.com - January 18 at 9:19 PM
News Icon2017 Small-Cap Biotech Watchlist: Takeaways for Investors (NYSEMKT:AST)
jutiagroup.com - January 18 at 4:17 PM
thestreet.com logoNoteworthy Wednesday Option Activity: AST, KITE, TDOC (NYSEMKT:AST)
www.thestreet.com - January 18 at 4:17 PM
finance.yahoo.com logoAsterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study (NYSEMKT:AST)
finance.yahoo.com - January 18 at 4:17 PM
prnewswire.com logoAsterias Announces Successful Commencement of Operations at ... - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - January 9 at 4:38 PM
finance.yahoo.com logoAsterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1 (NYSEMKT:AST)
finance.yahoo.com - January 9 at 4:38 PM
publicnow.com logoCurrent report No 1/2017 (NYSEMKT:AST)
www.publicnow.com - January 5 at 3:55 PM
finance.yahoo.com logoThe Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist (NYSEMKT:AST)
finance.yahoo.com - January 4 at 3:47 PM
News IconAsterias Biotherapeutics, Inc. (AST) - Brokers Update Their Views ... - NewsDen (NYSEMKT:AST)
newsden.net - January 2 at 8:19 PM
News IconUpside Alert: Delving into Shares of Asterias Biotherapeutics, Inc. (:AST) - Prospect Journal (NYSEMKT:AST)
prospectjournal.com - January 2 at 8:19 PM
capitalcube.com logoETFs with exposure to Asterias Biotherapeutics, Inc. : December 27, 2016 (NYSEMKT:AST)
www.capitalcube.com - December 27 at 3:57 PM
News IconAre There Catalysts to Propel This Stock Forward: Asterias Biotherapeutics, Inc. (:AST) - Prospect Journal (NYSEMKT:AST)
prospectjournal.com - December 26 at 3:34 PM
seekingalpha.com logoA Major Breakthrough In Modern Medicine: Regenerative Medicine Is Finally A Reality! (NYSEMKT:AST)
seekingalpha.com - December 26 at 8:28 AM
News IconIndicator Level Summary for Asterias Biotherapeutics Inc. (AST) - Yankee Analysts (NYSEMKT:AST)
yankeeanalysts.com - December 21 at 1:57 AM

Social

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?

4 analysts have issued 1 year target prices for Asterias Biotherapeutics' shares. Their predictions range from $5.50 to $10.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next twelve months.

When will Asterias Biotherapeutics announce their earnings?

Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

Who owns Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Thrivent Financial for Lutherans (0.89%), State Street Corp (0.49%) and Oxford Asset Management (0.11%). Company insiders that own Asterias Biotherapeutics stock include Alfred D Kingsley, Andrew Arno, Edward Wirth, Katharine E Spink, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt.

Who bought Asterias Biotherapeutics stock? Who is buying Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp and Oxford Asset Management. Company insiders that have bought Asterias Biotherapeutics stock in the last two years include Alfred D Kingsley, Andrew Arno, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt.

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Asterias Biotherapeutics stock cost?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.90.


Last Updated on 2/28/2017 by MarketBeat.com Staff